Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B7 | P56937 | 2/20 | 0.59 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.58 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4264788 | 1.00 | HSD17B7 (0.59) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL13656754 | 1.00 | HSD17B7 (0.59) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL9066656 | 0.91 | HSD17B7 (0.57) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL9066658 | 0.91 | HSD17B7 (0.57) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL9270145 | 0.87 | HSD17B7 (0.55) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL9066057 | 0.87 | HSD17B7 (0.55) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL9066061 | 0.87 | HSD17B7 (0.55) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL8077570 | 0.86 | HSD17B7 (0.54) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL7072009 | 0.86 | HSD17B7 (0.54) | HSD17B7SRD5A1SRD5A2 | |
| SCHEMBL4265826 | 0.85 | HSD17B7 (0.64) | HSD17B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467739-A4 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | claimed |
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | claimed |
| EP-1467739-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| WO-2003059293-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | claimed |
| US-7605152-B2 | 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1467739-A4 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-05-19 | — | — | US | disclosed |
| EP-1467739-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059293-A2 | 17-HYDROXY-4-AZA-ANDROSTAN-3-ONES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107416-A1 | 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators | SHBG, CYP19A1, NR5A1 | HSD17B7 12/4885SRD5A1 5/4885SRD5A2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.